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????????????
The calcium-binding protein S100A4 , which 
belongs to the S100 family, promotes metastasis in 
animal models 1）. S100A4 is expressed in the nucleus, 
cytoplasm, and extracellular space, and its functions 
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????????????????????????：The calcium-binding protein S100A4 belongs to the S100 family and is 
involved in fibrotic and inflammatory processes, in which tissue remodeling, cell motility, and epithelial–
mesenchymal transition play major roles. Cytoplasmic S100A4 is a marker of lung fibroblasts in pulmonary 
fibrosis；however, the effects of exogenous S100A4 on fibrotic and inflammatory processes in pulmonary 
fibrosis are unclear. This study examined the effects of exogenous S100A4 protein in mice with bleomycin-
induced pulmonary fibrosis.
???????：Bleomycin was administered to mice by intratracheal instillation on day 1. Intratracheal 
S100A4 protein was administered 4 times after bleomycin treatment. Bronchoalveolar lavage fluid was 
obtained and lung histological examinations were performed on day 14 after bleomycin administration. 
Lung tissue was homogenized on the same day to assess the mRNA expression of cytokines, fibroblast 
growth factors, and S100A4.
???????：Unexpectedly, we observed that the administration of exogenous S100A4 protein apparently 
reduced lung fibrosis in bleomycin-treated mice. In addition, the levels of lymphocyte accumulation and 
insulin-like growth factor-1 mRNA were significantly reduced in bleomycin-treated lung by S100A4 
administration.
???????????：Exogenous S100A4 protein attenuates bleomycin-induced pulmonary fibrosis in mice by 
reducing lymphocyte function and the levels of fibroblast growth factors.
?????????：S100A4；bleomycin-treated mice；pulmonary fibrosis；fibroblast growth factors
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include regulation of cell survival, motility, and inva­
sion 2〜4）. The human S100A4 gene is located at a fre­
quently reorganized gene cluster on chromosome 
1q21. It consists of four exons, the first two of which 
are noncoding 5）. Several studies have demonstrated 
roles for S100A4 in cancer advancement and the 
enhancement of metastasis 1,2）. Recent studies have 
reported that S100A4 is also associated with renal 
fibrosis, liver cirrhosis, pulmonary fibrosis, cardiac 
hypertrophy, rheumatoid arthritis, and neuronal inju­
ries 6）. In these diseases, endogenous S100A4 is 
involved in fibrotic and inflammatory processes, in 
which tissue remodeling, cell motility, and epithelial-
mesenchymal transition play major roles 6）. Further­
more, cytoplasmic S100A4 is a marker of lung fibro­
blasts in pulmonary fibrosis 7）；however, the effects of 
exogenous S100A4 on the fibrotic and inflammatory 
processes of pulmonary fibrosis remain unclear.
This study examined the effect of exacerbations by 
exogenous S100A4 in mice with bleomycin-induced 
pulmonary fibrosis and found an unexpected effect of 
this protein on pathogenesis. We discuss a novel ther­
apeutic role for S100A4 in fibrotic lung diseases.
?????????????????????
Animals
C57BL/6 mice were purchased from Japan SLC, Inc.
（Hamamatsu, Japan）. This study was approved by 
the Animal Ethics Committee of Dokkyo Medical Uni­
versity.
Bleomycin and S100A4 administration in mice
To investigate the direct synergic effect of S100A4 
in lung tissues inflammations, we demonstrated by 
intratracheal administration with the protein in bleo­
mycin-induced mice. Figure1 shows the study proto­
cols. Groups 1, 3, and 4 were treated with bleomycin 
to induce pulmonary fibrosis. Saline（bleomycin［－］）
or bleomycin sulfate（bleomycin［＋］；5 mg/kg body 
weight；Nippon Kayaku, Tokyo, Japan）was given by 
intratracheal administration to mice anesthetized with 
sodium pentobarbitone（50 mg/kg body weight）on 
day（D）1. Bleomycin（＋）mice, anesthetized by sodi­
um pentobarbitone, were given 50 µL S100A4（R&D, 
Minneapolis, MN）（500 ng/body to Group 3 or 50 ng/
body to Group 4）or saline（Group 1）by intratracheal 
administration 4 times on D3, D4, D7, and D10. In 
addition, bleomycin（－）mice（saline；Group 2）were 
administered 500 ng/mL S100A4. Using an aseptic 
technique, a single incision was made in the neck and 
the muscle tissue covering the trachea was snipped to 
expose the tracheal rings. Bronchoalveolar lavage
（BAL）fluid was collected on D14 after bleomycin or 
saline administration, and histological examination of 
the lungs was performed on D14.
BAL
BAL and cell counting were performed as described 
previously 8）. The cells in the BAL fluid were harvest­
ed and counted.
Expression of cytokines, fibroblast growth factor, and 
S100A4 mRNA in lung tissue
The right lobes of the lung were harvested and 
stored at －80℃ for several days after washing with 
phosphate-buffered saline. The tissue was thawed at 
0℃ in 1 mL TRIzol reagent（Invitrogen, Carlsbad, 
CA）and then homogenized with a microhomogenizer
（10,000×g, 90s）. Total RNA extraction was perfor­
med by a modified guanidine isothiocyanate-phenol-
chloroform method, as described previously 9）. The 
resultant complementary DNA products were diluted 
in Tris buffer and used for real-time quantitative 
PCR.
Real-time quantitative PCR
Interleukin（IL）-4, IL-5, IL-13, interferon（IFN）-g , 
transforming growth factor（TGF）-b1, insulin-like 
growth factor（IGF）-1, platelet-derived growth factor
（PDGF）-AA, and S100A4 mRNA expression levels 
were quantified by real-time RT-PCR（ABI/PRISM 
7000；Applied Biosystems, Foster City, CA）. PCR 
data were analyzed using ABI/PRISM 7000 SDS v1.0 
software（Applied Biosystems）, with b-actin as the 
internal control. The PCR conditions were described 
previously 9）. The mouse mRNA primers were pur­
chased from Takara Bio USA（Madison, WI）.
Histopathology
Paraformaldehyde in phosphate buffer was perfused 
into the left lung at a constant pressure. After fixa­
tion, lung tissues were embedded in paraffin and sec­
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tioned with a microtome at a thickness of 4 µm. The 
sections were mounted on slides and stained with 
hematoxylin and eosin（HE）. For each mouse, four 
sections of the whole lung stained with HE were 
selected randomly. The severity of lung fibrosis was 
analyzed as described previously 9）. To obtain photo­
micrographs, a fluorescence microscope（model 
EX41；Olympus America, Melville, NY）with a ×20 
lens and an Olympus Magna Fire camera was used.
Statistical analysis
Data are expressed as means±standard deviation
（SD）. Statistical significance was determined by Stu­
dent’s t-test（two-tailed）for two groups or one-way 
analysis of variance（with Tukey’s multiple compari­
sons test）for three or more groups. P values ＜0.05 
were considered to be significant. JMP software（Ver­
sion 7.0 for Mac；SAS Institute, Cary, NC）was used 
for statistical analyses.
???????
Cells in BAL fluid from bleomycin-treated mice with 
or without S100A4 administration
To examine the effect of S100A4, cell populations in 
the BAL fluid taken from each treated group and con­
trol mice administered saline alone were examined
（Figure 2A）. The number of each cell type following 
administration with bleomycin alone（Group 1）was 
compared with that in the control group（representing 
the basal level）. The number of total cells and macro­
phages was not significantly different among each 
study group. Eosinophilia was not observed（data not 
shown）. In contrast, treatment with S100A4 alone
（Group 2）increased the number of neutrophils, which 
was decreased with pre-administration of bleomycin 
in Group 3（0.7±0.1×10 5 cells）and Group 4（0.1±
0.01×10 5 cells）, although the number was greater in 
Group 3 than in Group 1（0.2±0.2×10 5 cells）. Nota­
bly, bleomycin-induced lymphocytosis was significant­
ly attenuated by treatment with S100A4, the effect of 
which when administered alone was modest. On the 
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????????　Schema of the study protocols.
Group 1, mouse model of bleomycin-treated pulmonary fibrosis with saline；Group 2, mouse 
model of S100A4 only（500 ng/mouse）；Group 3, mouse model of bleomycin-treated pulmonary 
fibrosis with S100A4（500 ng/mouse）；and Group 4, mouse model of bleomycin-treated pulmo­
nary fibrosis with S100A4（50 ng/mouse）. BAL fluid was taken and lungs were analyzed for the 
expression of mRNA and histology on day 14（D14）.
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±0.6）when compared to saline alone（0 .5±0 .1）. 
These results indicated the unexpected effect that 
S100A4 attenuated bleomycin-induced pulmonary 
fibrosis.
Expression of cytokine and fibroblast growth factor 
mRNA in lung tissue of bleomycin-treated mice with 
or without S100A4
Since analysis for cytokines and fibroblast growth 
factors（IGF-1, PDGF, and TGF-b）at the protein 
level was affected by their widely varying concentra­
tions（data not shown）, mRNA expression in whole 
lung tissue was investigated on D14 after bleomycin 
administration. T helper（Th）cytokines as well as 
growth factors have been suggested to be involved in 
the pathogenesis of pulmonary fibrosis. Administration 
of S100A4 alone showed a tendency for increased 
mRNA expression of Th2 cytokines（IL-4, IL-5, and 
IL-13）as compared with a Th1 cytokine（IFN-g）
other hand, the number of total cells, macrophages, 
and neutrophils was significantly（P＜0.05）greater in 
Group 2（2.8±2.0×10 5 cells, 0.7±0.1×10 5 cells, and 
1.8±1.6×10 5 cells, respectively）than in saline alone
（0.1±0.1×10 5 cells, 0.1±0.1×10 5 cells , and 0.1±0.1
×10 7 cells, respectively）.
Histopathological analysis in bleomycin-treated mice 
with or without S100A4 administration
We performed histopathological analysis on D14 of 
the lungs of bleomycin-treated mice that had been 
administered（Groups 3 and 4）or not administered
（Group 1）S100A4（Figure 2B）. The lung fibrosis 
score（Figure 2C）was significantly reduced in Group 
3（3.3±0.6）compared with Group 1（5.0±0.8）. These 
results indicated that bleomycin-induced pulmonary 
fibrosis could be reduced by treatment with S100A4. 
In contrast, the administration of S100A4 alone
（Group 2）increased（P＜0.001）pulmonary fibrosis（2.5
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1：relative ratio, 3.3±0.8）was significantly augment­
ed by S100A4（Group 3：relative ratio, 19.0±6.8）. 
The expression of IL-4, IL-5, and IL-13 mRNA was 
significantly greater in Group 2（14.6±1.4, P＜0.01, 
17.3±10.7, P＜0.05, and 8.4±6.6, P＜0.05, respective­
ly）than in saline only. There was no significant differ­
ences in the expression of IFN-gmRNA between 
Group 2 and saline alone. As for the fibroblast growth 
factors（Figure 3B）, a modest increase in TGF-b 1 
mRNA expression was similarly observed in bleomy­
cin-treated lungs（Groups 1, 3, and 4）as compared 
with the control, whereas S100A4 itself had no appar­
ent effect on expression. S100A4 alone（Group 2）sig­
nificantly induced PDGF-AA mRNA expression；
however, it did not influence the expression induced 
by bleomycin treatment（Groups 1, 3, and 4）. Notably, 
the bleomycin treatment-induced expression of IGF-1 
mRNA（Group 1：relative ratio, 12.0±0.5）was signifi­
cantly reduced by S100A4, which showed clearly a 
（Group 2）（Figure 3A）. Among the bleomycin-treated 
groups（Groups 1, 3, and 4）, there was no significant 
difference in the expression levels of IFN-g , IL-4, and 
IL-5 , regardless of S100A4 administration. IL-13 
mRNA expression in bleomycin-treated lungs（Group 
Bleomycin
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????????　 The types of cells（?）in BAL fluid in bleomycin-
treated mice.
The number of cells（×105）in BAL fluid was assessed on 
day 14. Saline-treated mice（bleomycin［－］）were adminis­
tered sa l ine intratracheal ly four t imes as contro ls . 
Histopathological analysis（?）of the lungs of bleomycin-treat­
ed mice. For histopathological analysis, lung sections were 
stained with HE. The scale bar represents 500 µm. Original 
magnification, ×100. B：Quantification of lung fibrosis（?）in 
lung tissue by score. Data are presented as means±SD for 
each group. ＊P＜0.05 compared with bleomycin-treated mice 
administered saline. N.S., no significant difference.
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the administration of exogenous S100A4 attenuated 
the expression of endogenous S100A4 mRNA by a 
negative feedback loop.
??????????
We demonstrated that exogenous S100A4 amelio­
rated bleomycin-induced lung fibrosis with a reduc­
tion of lymphocyte accumulation and expression of 
IGF-1 mRNA in lung tissue. S100A4 is expressed in 
the cytoplasm and exported extracellularly 3,4）, is 
involved in cellular proliferation and the development 
of fibrosis 6）, and is expressed by lung fibroblasts in 
interstitial pneumonia and malignant tumor cells 6）. 
The observed therapeutic effects of exogenous 
S100A4 administration was contrary to our expecta­
tions, although endogenous S100A4 mRNA expression 
was attenuated in whole lung tissue, such as observed 
for the negative feedback mechanism via receptor for 
advanced glycation end products（RAGE）, a ligand of 
dose-dependent effect（Group 3：relative ratio, 7.0±
0.2）. Conversely, administration of S100A4 alone
（Group 2）has a modest effect on the expression of 
IGF-1 mRNA. The expression of PDGF-AA and 
IGF-1 mRNA was significantly greater in Group 2（9.5
±1.6, P＜0.01, and 1.8±0.5, P＜0.05, respectively）
than in saline only. There was no significant differenc­
es in the expression of TGF-b 1 mRNA between 
Group 2 and saline alone. Finally, we observed that 
bleomycin treatment significantly increased S100A4 
mRNA expression（Group 1：relative ratio, 2.6±0.7）
in lung tissue, which was significantly reduced in mice 
administered exogenous S100A4 at a high dose
（Group 2：relative ratio, 0.8±0.5；Group 3：relative 
ratio, 1 .3±0.9）compared with those administered 
S100A4 at a low dose（Group 4：relative ratio, 1.6±
1.1）（Figure 3C）. There was no significant differences 
in the expression of S100A4 mRNA between Group 2
（0.8±0.5）and saline. These results demonstrated that 
0
2
4
6
8
10
Control Group 1 Group 2 Group 3 Group 4
N.S
R
el
at
iv
e 
 r
at
io
N.S
N.S
Bleomycin ― ＋ ― ＋ ＋
S100A4(ng/body) ― ― ＋ 500 50
INF‐γ
0
10
20
30
Control Group 1 Group 2 Group 3 Group 4
IL-4
R
el
at
iv
e 
 r
at
io
N.S
N.S
Bleomycin ― ＋ ― ＋ ＋
S100A4(ng/body) ― ― ＋ 500 50
**
0
10
20
30
40
Control Group 1 Group 2 Group 3 Group 4
IL-5
*
R
el
at
iv
e 
 r
at
io
N.S
N.S
Bleomycin ― ＋ ― ＋ ＋
S100A4(ng/body) ― ― ＋ 500 50
R
el
at
iv
e 
 r
at
io
Bleomycin ― ＋ ― ＋ ＋
S100A4(ng/body) ― ― ＋ 500 50
0
10
20
30
40
Control Group 1 Group 2 Group 3 Group 4
IL-13
N.S
**
*
????????　?
S100A4 protein attenuates bleomycin-induced pulmonary fibrosis??（2）（2016） 111
latter two inflammatory cells are involved in the pul­
monary pathogenesis of both fibrogenic diseases and 
experimental models. Indeed, we observed an influ­
ence of S100A4 administration on the numbers of 
lymphocytes and neutrophils, but not eosinophils and 
macrophages, in vivo. Exogenous S100A4 reduced the 
pulmonary influx of lymphocytes in bleomycin-treated 
mice, which was coincident with an improvement of 
fibrogenesis. In contrast, neutrophil influx was more 
pronounced following S100A4 administration alone 
rather than with bleomycin. Epithelial-mesenchymal 
transition and bone marrow progenitors reportedly 
contribute to S100A4-positive fibroblasts in bleomy­
cin-induced lung fibrosis. Furthermore, we observed 
that lung fibrosis could be induced by S100A4 alone 
to a modest but significant extent as compared with 
control, indicating a fibrogenic effect that might 
involve the observed neutrophil influx. However, in 
terms of the pathogenesis of bleomycin-induced lung 
the S100 family. This endogenous down-regulation 
may be implicated in the effect of exogenous S100A4 
on fibrogenesis；however, other mechanisms may also 
be involved.
RAGE is expressed on a range of cells, including 
endothelial cells, smooth muscle cells, epithelial cells, 
lymphocytes, macrophages, and neutrophils 10）. The 
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????????　 mRNA expression of cytokines and fibroblast 
growth factors in lung tissue.
The mRNA expression of Th1-type（IFN-g）/Th2-type
（IL-4, IL-5 , and IL-13）cytokines（?）and fibroblast 
growth factors（TGF-b1, IGF-1, and PDGF-AA）（?）in 
lung tissue from each group is shown. Expression of 
S100A4（?）mRNA in lung tissue from each group. 
Expression is shown as a ratio relative to expression in 
the lung of saline-treated mice（bleomycin［－］and 
S100A4［－］）as controls. Data are presented as means±
SD for each group. ＊P＜0.05 and ＊＊P＜0.01 compared 
with bleomycin-treated mice administered saline. N.S., no 
significant difference.
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the initiation of TGF-b  signaling 16）. Remarkably, the 
overexpression of Smad7 is known to prevent bleomy­
cin-induced pulmonary fibrosis 17）. Furthermore, Tang 
et al. demonstrated that overexpressing latent TGF-
b1 protected against bleomycin-induced lung injury 
via overexpressed Smad7-mediated inhibition of 
TGF-b/Smad2/3 signaling and enhancement of regu­
latory T cell responses 18）. Therefore, the ameliorating 
effect of S100A4 in this pulmonary fibrosis model 
might be a result of the reinforcement of the function 
of Smad7 to regulate TGF-b/Smad2/3 signaling in a 
negative feedback loop.
In conclusion, the present study demonstrates that 
exogenous S100A4 attenuates bleomycin-induced 
lung fibrosis. On the other hand, the functions of 
exogenous S100A4 might be regulated by the back­
ground of various inflammations in lung tissues. 
Although the exact details underlying the S100A4-
mediated regulation are still unknown, further clarifi­
cation of these complex mechanisms is needed to pro­
vide an understanding of the pathogenesis of 
pulmonary fibrosis and the development of new thera­
peutic strategies.
?????????????
BAL：bronchoalveolar lavage
IFN：interferon
IGF：insulin-like growth factor
IL：interleukin
N.S.：no significant difference
PDGF：platelet-derived growth factor
SD：standard deviation
TGF-b：transforming growth factor-b
Th：T helper
RAGE；receptor for advanced glycation end prod­
ucts
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fibrosis, we focused on the therapeutic effect of 
S100A4 , which was completely unexpected. To 
explain the mechanism underlying this effect, the 
attenuation of lymphocyte influx may be involved, 
which is suggested by the positive correlation 
between the levels of fibrogenesis and lymphocyte 
influx in the current study, although cell type was not 
analyzed in detail. However, we could not identify an 
apparent correlation between the expression of any 
cytokine and fibrogenesis, while Th2-type cytokines, 
such as IL-4 and IL-13, are reportedly involved in 
the pathogenesis of lung fibrosis. Several studies 8,9）
stated that Th2-dominant inflammation was not 
required for the development, severity, or prognosis 
of bleomycin-induced pulmonary fibrosis. In our 
results, Th2-type inflammation did not seem to play a 
major role in the development of fibrosis. Thus, sup­
pressing an unknown function of lymphocytes may be 
related to the therapeutic effect of S100A4 on the 
development of fibrosis.
The current study indicated another effect of 
S100A4；namely, the reduced expression of IGF-1 
mRNA, which is produced from osteoclasts and fibro­
blasts 11）and plays an important role as a prosurvival 
factor for fibroblasts in bleomycin-induced lung inju­
ry 12）. A noteworthy fact is that the levels of IGF-1 
mRNA were positively correlated with the level of 
fibrosis following bleomycin treatment. It has been 
already reported that IGF-1 promotes the survival of 
lymphocytes 13）. Thus, S100A4 may mediate cross-talk 
regulation between IGF-1 gene expression and the 
suppression of lymphocyte influx to ameliorate bleo­
mycin-induced pulmonary fibrosis, although the pre­
cise mechanism is still unknown. Another growth fac­
tor, TGF-b , which is a major fibroblast growth factor, 
also plays important roles in the development of fibro­
sis in several organs 14）. TGF-b1 expression was not 
reduced by S100A4 administration in the current 
study, whereas Tomcik et al. demonstrated that 
S100A4 amplifies TGF-b-induced fibroblast activation 
in systemic sclerosis and that excess amounts of 
S100A4 activated TGF-b/Smad2/3 signaling in fibro­
blasts, resulting in increases in p-Smad3 15）, which was 
suggested to activate collagen synthesis at the mRNA 
level. Conversely, they demonstrated that S100A4 
also up-regulated Smad7 expression, which inhibits 
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